Graves Ophthalmopathy: Clinical Trials

80 completed, 35 recruiting, 30 unknown, 16 not yet recruiting. 52 Phase 3, 39 Phase 2, 31 Not applicable, 25 Phase 4, 21 Phase 1.

By phase and status

Phase	Trials	Status
Phase 3	52	Completed 20, Recruiting 8, Active not recruiting 7, Unknown 6, Not yet recruiting 4, Terminated 4, Withdrawn 3
Phase 2	39	Completed 15, Recruiting 5, Terminated 5, Unknown 5, Withdrawn 4, Not yet recruiting 3, Active not recruiting 2
Not applicable	31	Completed 11, Unknown 10, Recruiting 4, Active not recruiting 2, Enrolling by invitation 2, Not yet recruiting 1, Terminated 1
Phase 4	25	Completed 8, Recruiting 6, Not yet recruiting 4, Unknown 4, Withdrawn 2, Terminated 1
Phase 1	21	Completed 10, Recruiting 5, Active not recruiting 2, Not yet recruiting 2, Terminated 1, Withdrawn 1
Early Phase 1	2	Recruiting 1, Unknown 1

Follow Graves Ophthalmopathy: new trials by email Literature Review of Graves Ophthalmopathy trials Research Report on Graves Ophthalmopathy

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Open-Label Extension Study of MHB018A in Patients With Thyroid Eye Disease MHB018A injection - Thyroid Eye Disease (TED)	Phase 3	Not yet recruiting	Minghui Pharmaceutical (Hangzhou) Ltd	219	2027-07-01	2026-06-04
Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO) Atorvastatin - Graves Disease, Graves Disease (Basedow's Disease)	Phase 2	Not yet recruiting	Region Skane	554	2026-11-01	2026-10-20
Transconjunctival Versus Transcutaneous Betamethasone for Upper Eyelid Retraction in TED Betamethasone - Thyroid Eye Disease	Not applicable	Not yet recruiting	Assiut University	54	2026-10-10	2026-10-08
Treatment of Active Thyroid Eye Disease With MHB018A in a Randomized, Placebo-Controlled Study MHB018A, MHB018A placebo - Thyroid Eye Disease, TED	Phase 3	Recruiting	Minghui Pharmaceutical (Hangzhou) Ltd	84	2026-09-28	2026-10-14
Treatment of Chronic Thyroid Eye Disease With MHB018A MHB018A injection, MHB018A injection Placebo - Thyroid Eye Disease, TED	Phase 3	Recruiting	Minghui Pharmaceutical (Hangzhou) Ltd	135	2026-09-24	2026-10-14
An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab veligrotrug (LUMVOA™) - Thyroid Eye Disease	Phase 4	Not yet recruiting	Viridian Therapeutics, Inc.	30	2026-09-01	2026-09-21
Early Risk Stratification of Thyroid Eye Disease in Newly Diagnosed Graves' Disease Study-related ophthalmological assessment and biospecimen collection, Blood biomarkers and standardized blood samples including thyroid function status - Graves' Orbitopathy, Thyroid Eye Disease, TED		Not yet recruiting	University of Copenhagen	430	2026-09-01	2026-09-10
Study of Atorvastatin and Its Effects in Clinical and Radiological Aspects in Patients With Moderate-to-Severe Thyroid Eye Disease Atorvastatin, methylprednisolone (IVMP) - Thyroid Eye Disease, Graves Ophthalmopathy	Phase 1	Not yet recruiting	Banu Aji Dibyasakti	64	2026-08-30	2026-08-13
Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED) linsitinib, Placebo - Thyroid Eye Disease, TED, Graves Orbitopathy	Phase 3	Recruiting	Sling Therapeutics, Inc.	130	2026-08-04	2026-10-20
Teprotumumab N01 Versus Methylprednisolone After Urgent Orbital Decompression for Dysthyroid Optic Neuropathy Teprotumumab N01, Intravenous Methylprednisolone (IVMP) - Thyroid Eye Disease, TED, Graves Ophthalmopathy	Phase 2	Not yet recruiting	Sun Yat-sen University	60	2026-08-01	2026-05-19
A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Active Thyroid Eye Disease KHN939, Placebo - Thyroid Eye Disease	Phase 3	Not yet recruiting	Beijing Kanghong Biological Medicine Co., Ltd.	60	2026-08-01	2026-07-23
A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Inactive Thyroid Eye Disease KHN939, Placebo - Thyroid Eye Disease	Phase 3	Not yet recruiting	Beijing Kanghong Biological Medicine Co., Ltd.	117	2026-08-01	2026-07-23
A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease Teprotumumab N01, Methylprednisolone - Thyroid Eye Disease	Phase 4	Recruiting	Innovent Biologics (Suzhou) Co. Ltd.	92	2026-07-30	2026-08-13
Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease ETHY-001, Placebo - Thyroid Eye Disease (TED), Graves' Disease	Phase 1	Recruiting	Ethyreal Bio, Inc.	72	2026-07-06	2026-10-21
Clinical Validation of AI-Based Quantitative Eye Movement Analysis From Smartphone 9-Gaze Videos (Glandy EOM) Glandy EOM (AI-based quantitative eye movement analysis software) - Ocular Motility Disorders, Strabismus		Not yet recruiting	THYROSCOPE INC.	1000	2026-07-01	2026-06-03
Prospective Observational Study of Smartphone-Based AI Self-Monitoring During Non-Surgical Treatment for Thyroid Eye Disease (THYROSCOPE) Smartphone-based AI self-monitoring application (Glandy CAS/EXO/LID) - Thyroid Eye Disease (TED), Graves Ophthalmopathy		Not yet recruiting	THYROSCOPE INC.	200	2026-07-01	2026-06-03
A Study of IBI3031 in Participants With Thyroid Eye Disease IBI3031, placebo - Thyroid Eye Disease	Phase 1	Recruiting	Innovent Biologics (Suzhou) Co. Ltd.	66	2026-06-30	2026-07-14
A Clinical Study of Cizutamig in Thyroid Eye Disease Cizutamig will be dosed according to the protocol. - Thyroid Eye Disease, TED	Phase 1	Recruiting	Candid Therapeutics	38	2026-05-08	2026-09-01
An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease AMG 732 - Thyroid Eye Disease	Phase 2	Recruiting	Amgen	30	2026-05-07	2026-07-23
A Study of VV-14305 for the Treatment of Thyroid Eye Disease VV-14305, Sham (No Treatment) - Thyroid Eye Disease (TED)	Phase 1 / Phase 2	Recruiting	Kriya Therapeutics, Inc.	135	2026-05-01	2026-08-27

Showing 20 of 197. Sign in to see all of them.

Narrower conditions

Graves Disease (36)  ·  Exophthalmos (17)  ·  Thyroid Diseases (11)  ·  Eye Diseases (10)  ·  Autoimmune Diseases (9)  ·  Hyperthyroidism (9)  ·  Endocrine System Diseases (6)  ·  Orbital Diseases (4)  ·  Eye Diseases, Hereditary (3)  ·  Hashimoto Disease (3)  ·  Immune System Diseases (3)  ·  Insulin-Like Growth Factor I, Resistance To (3)  ·  Diplopia (2)  ·  Dry Eye Syndromes (2)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (197)  ·  Genetic Diseases, Inborn (197)  ·  Goiter (195)  ·  Eye Diseases, Hereditary (194)  ·  Immune System Diseases (194)  ·  Orbital Diseases (193)  ·  Endocrine System Diseases (191)  ·  Autoimmune Diseases (188)  ·  Hyperthyroidism (188)  ·  Eye Diseases (187)  ·  Thyroid Diseases (186)  ·  Exophthalmos (180)  ·  Graves Disease (161)  ·  Nervous System Diseases (6)  ·  Pathological Conditions, Signs and Symptoms (6)

Interventions

Methylprednisolone (22)  ·  teprotumumab (15)  ·  Sodium Chloride (6)  ·  Atorvastatin (5)  ·  Methylprednisolone Hemisuccinate (5)  ·  tocilizumab (5)  ·  Glucocorticoids (4)  ·  Methimazole (4)  ·  Rituximab (4)  ·  Saline Solution (4)  ·  Selenium (4)  ·  Sirolimus (4)  ·  3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol (3)  ·  Bimatoprost (3)  ·  Doxycycline (3)

Sponsors

Amgen (14)  ·  Sun Yat-sen University (14)  ·  University of Pisa (11)  ·  Viridian Therapeutics, Inc. (9)  ·  Shanghai Changzheng Hospital (7)  ·  Innovent Biologics (Suzhou) Co. Ltd. (6)  ·  Minghui Pharmaceutical (Hangzhou) Ltd (6)  ·  Immunovant Sciences GmbH (5)  ·  Medical University of Warsaw (4)  ·  Assiut University (3)  ·  Medical University of Vienna (3)  ·  National Taiwan University Hospital (3)  ·  Sling Therapeutics, Inc. (3)  ·  University of Sao Paulo (3)  ·  Beijing Kanghong Biological Medicine Co., Ltd. (2)

Countries

China (54)  ·  United States (53)  ·  Italy (24)  ·  Spain (23)  ·  Germany (20)  ·  United Kingdom (19)  ·  Poland (16)  ·  France (13)  ·  Australia (12)  ·  Canada (8)  ·  Hungary (7)  ·  Taiwan (7)  ·  Turkey (Türkiye) (7)  ·  Austria (5)  ·  Brazil (5)

Top investigators

Dan Liang (3)  ·  Dan Liang, MD (3)  ·  Mohsen B Kashkouli, MD (2)  ·  Ahmed Abdelal, MD (1)  ·  Ahmed Abdelnasser, Lecturer (1)  ·  Andrea L. Kossler, M.D. (1)  ·  Audrey Lee Geok Looi, MMed(Ophth), FRCS(Ed) (1)  ·  Babak Babsharif, MD (1)  ·  Bingyin Shi (1)

Results publications

PMID 33768488, PMID 41066062, PMID 10634372, PMID 10873993, PMID 12608932, PMID 12848966, PMID 14398978, PMID 16140250, PMID 16286624, PMID 16704685, PMID 17057811, PMID 1802923, PMID 18299459, PMID 19643971, PMID 19865824, PMID 20181974, PMID 20305505, PMID 21215658, PMID 21730841, PMID 21852080, PMID 21915479, PMID 22124787, PMID 22287122, PMID 22442048, PMID 22443978, PMID 22752189, PMID 22968823, PMID 23253433, PMID 23874630, PMID 24145858, PMID 24606088, PMID 24651704, PMID 25343233, PMID 26221138, PMID 27493796, PMID 27797318, PMID 28467880, PMID 29026936, PMID 29942184, PMID 30420883, PMID 30679116, PMID 31496266, PMID 31657648, PMID 31885895, PMID 31893319, PMID 31971679, PMID 32140081, PMID 32280513, PMID 32832143, PMID 33012142

NIH funding

2023 (6), 2017 (2), 2004 (1), 2009 (1), 2014 (1), 2015 (1), R01DK077814 (1), UL1RR024150 (1), UL1TR000005 (1)